TOKYO-METROPOLITAN-GOV
The Tokyo Metropolitan Government (TMG) will be holding its SusHi Tech Tokyo 2024 event in the Tokyo Bay area in April and May of 2024, promoting TMG’s “Sustainable High City Tech Tokyo (SusHi Tech Tokyo)” vision for the creation of sustainable new value.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231101664569/en/
SusHi Tech Tokyo 2024 programs (Graphic: Business Wire)
The event is intended to bring together Tokyo’s innovation creators, solving the issues faced by the world’s urban centers, and to share their models for the future globally.
Applications are now being accepted for participants and exhibitors in the Global Startup Program, as well as for sponsoring partners.
SusHi Tech Tokyo 2024 - Key Points |
・SusHi Tech Tokyo 2024 is a large scale event being held in April and May of 2024
|
・The event will be divided into three programs:
|
・Applications are now being accepted for Global Startup Program exhibitors, sponsors, and pitch contest entrants . Tickets are also now on sale. (details below)
|
・Further information is available on the homepages and social media for each program.
|
・Details about the themes, venues, and contents of the Global Startup Program and the Showcase Program will be announced. Please see the attached sheets for details. URL: https://www.metro.tokyo.lg.jp/english/topics/2023/documents/1031_01_01.pdf |
Calls for exhibitors, sponsors, etc.
Entries for the “SusHi Tech Challenge” Global Startup Program Pitch Contest
Languages: English
Prize: JPY 10 million to the winning company, other prizes TBD
Entry period: from Friday, October 27, 2023 to Friday, December 22, 2023
Details and Entry form:
https://sushi-tech-tokyo.agorize.com/en/challenges/pitchcontest-exhibition?lang=en
Applications for Global Startup Program booth exhibitors
Languages: English
Entry period: from Friday, October 27, 2023 to Friday, December 22, 2023
Details and Application form:
https://sushi-tech-tokyo.agorize.com/en/challenges/pitchcontest-exhibition?lang=en
Global Startup Program event tickets
Early Bird Sale! Until Wednesday, January 31, 2024
Details:
https://sushi-tech-tokyo2024.eventos.tokyo/web/portal/749/event/7935/users/login/?ticketLargeCategoryId=2465&language=eng
Sponsor partnerships for the Global Startup Program
Supporting Partner
We are looking for sponsors who share our vision for the SusHi Tech Tokyo 2024 Global Startup Program
Details and application: https://www.sushitech-startup.metro.tokyo.lg.jp/en/sponsors/
Ambassador
We are looking for ambassadors to help us promote the event.
Details and application: https://www.sushitech-startup.metro.tokyo.lg.jp/en/recruiting-ambassador/
Partner Event
We are seeking partnerships with events that align with our objectives and wish to collaborate with the SusHi Tech Tokyo 2024 Global Startup Program, particularly those scheduled to take place approximately 2 weeks before or after the program event dates (May 15-16).
Details and application: https://www.sushitech-startup.metro.tokyo.lg.jp/en/related-events/
Further Information
SusHi Tech Tokyo 2024 Global Startup Program
Site URL: https://www.sushitech-startup.metro.tokyo.lg.jp/en/
X: @STT2024GSP_EN
LinkedIn: https://www.linkedin.com/company/sushi-tech-tokyo-gsp-official-account
SusHi Tech Tokyo 2024 Showcase Program
Site URL: https://www.sushitechtokyo2024-sc.metro.tokyo.lg.jp/?language=eng
X: @SusHiTech_eSG
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231101664569/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 202525.4.2025 14:00:00 CEST | Press release
Incyte (Nasdaq:INCY) today announced that the Company will present new early-stage data from its oncology portfolio at the American Association of Cancer Research (AACR) Annual Meeting 2025 in Chicago, IL, from April 25–30. “At AACR we will be presenting data from early-stage programs across our oncology portfolio, including for patients with myeloproliferative neoplasms, ovarian cancer and other solid tumors,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. “These data will guide our approach as we advance our pipeline and seek to transform the treatment landscape for patients with cancer and myeloproliferative neoplasms.” Abstracts accepted for presentation at AACR include: Mini Symposium INCB177054 INCB177054: A Novel, Potent, Orally Bioavailable DGKα/ζ Dual Inhibitor Enhances T-Cell Function and Demonstrates Potent Antitumor Activity (Session Title: Novel Antitumor Agents. April 28, 4:50 p.m. – 5:05 p.m. ET (3:50 p.m. – 4:05 p.m. CT). Abstract #
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom